| ATAIBECKLEY INC. O.N. |
| USA |
| Gesundheit |
| US04650F1012 / A41WEP |
| B72 (Frankfurt) / ATAI (NASDAQ) |
| FRA:B72, ETR:B72, B72:GR, NASDAQ:ATAI |
| - |
| https://www.ataibeckley.c.. |
|
AtaiBeckley Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative psychedelic-based therapeutics and neuroplastogens to treat mental health disorders. The company was formed through the strategic combination of atai Li..
>Volltext.. |
| 1249.5 Mio. EUR |
| 1033.11 Mio. EUR |
| 3.48 Mio. EUR |
| -97.68 Mio. EUR |
| -561.07 Mio. EUR |
| -1.96 EUR |
| 1.76 Mio. EUR |
| 72.51 Mio. EUR |
| -90.01 Mio. EUR |
| 10.91 |
| 1123.76% |
| -1442.02% |
| - |
| - |
| - |
| ATAIBECKLEY, ATAI BECKLEY |
| 20.04.26 |
|
||||
|